Compare GSK plc (GSK) vs Vipshop Holdings Ltd - ADR (VIPS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Vipshop Holdings Ltd - ADR — how do they compare? GSK plc trades at $46.63 (market cap $91.88B), while Vipshop Holdings Ltd - ADR trades at $12.99 (market cap $6.05B). The key difference: GSK plc is far larger — about 15.2× Vipshop Holdings Ltd - ADR's market cap, and Vipshop Holdings Ltd - ADR pays the higher dividend (4.87%). Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and Vipshop Holdings Ltd - ADR for 49 Days on average.
| GSK | VIPS | |
|---|---|---|
Market Cap | $91.88B | $6.05B |
Volume | 7,730,529 | 3,719,230 |
Sector | Health | Consumer Cyclical |
52-Week High | $61.18 | $20.29 |
52-Week Low | $43.24 | $12.09 |
Typical Hold Time | 93 Days | 49 Days |
Enterprise Value | $111.88B | $2.87B |
Dividend Yield | 3.9% | 4.87% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $47.02, up 0.9% with a P/E of 14.89, trading below industry averages. The stock shows strong profitability with 72.73% gross margins and 29.73% ROE, though technical indicators signal bearish momentum. Recent earnings beats and strategic oncology investments highlight growth potential amid patent cliff concerns.
GSK's valuation appears attractive with earnings momentum, but faces headwinds from technical weakness and HIV patent expirations. The bullish analyst sentiment (31% buy ratings) and pipeline innovation provide upside, while cost-saving initiatives and dividend yield offer stability. Key risks include competitive pressures and execution on £40B sales targets.
Vipshop Holdings trades at $12.77, showing modest daily gains of 0.16%. The stock presents compelling valuation metrics with a P/E of 4.1 and P/S of 0.4, trading below book value. Recent earnings show mixed performance with Q2 2026 missing expectations, though profitability remains strong with 9.82% net margins. Technical indicators show a bullish overall signal while oscillators remain neutral, with key support at $12.
The investment case centers on deep valuation discounts and strong profitability metrics, though revenue stagnation and consumer headwinds present challenges. Analyst consensus targets $16.17, offering 27% upside potential. Key risks include Chinese consumer sentiment weakness and competitive pressures in the off-price retail sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Vipshop Holdings Ltd - ADR
Vipshop Holdings Ltd is an online discount retailer for brands in China. The company offers branded products to consumers in China through flash sales on its vipshop.com, vip.com and lefeng.com websites. Flash sales represent an online retail format combining the advantages of e-commerce and discount sales through selling a finite quantity of discounted products or services online for a limited period of time. It deals in a wide range of products and services for consumers specializing in branded cosmetics, apparel, healthcare products, food and other consumer products. Its operating segment includes Vip.com and Shan Shan Outlets. The company generates maximum revenue from Vip.com segment.
Read more on VIPS →
